Results 71 to 80 of about 807 (164)

Drug treatments for covid-19: living systematic review and network meta-analysis [PDF]

, 2021
Objective To compare the effects of treatments for coronavirus disease 2019 (covid-19). Design Living systematic review and network meta-analysis. Data sources
Agarwal A, Agoritsas T, Bartoszko JJ, Brignardello-Petersen R, Chu DK, Couban R, Cusano E, Darzi A, Devji T, Fang B, Fang C, Flottorp SA, Foroutan F, Ge L, Ghadimi M, Guyatt GH, Han MA, Heels-Ansdell D, Honarmand K, Hou L, Hou X, Ibrahim Q, Izcovich A, Khamis A, Kum E, Lam B, Lamontagne F, Liu Q, Loeb M, Marcucci M, Martinez JPD, McLeod SL, Motaghi S, Murthy S, Mustafa RA, Neary JD, Pardo-Hernandez H, Qasim A, Rada G, Riaz IB, Rochwerg B, Sadeghirad B, Sekercioglu N, Sheng L, Siemieniuk RAC, Sreekanta A, Switzer C, Tendal B, Thabane L, Tomlinson G, Turner T, Vandvik PO, Vernooij RWM, Viteri-García A, Wang Y, Yao L, Ye Z, Zeraatkar D   +57 more
core   +1 more source

Disruption of Spike Priming in Virus Entry: Tetrandrine as a Pan‐Coronavirus Inhibitor

MedComm, Volume 6, Issue 9, September 2025.
Tetrandrine inhibits the infection of HCoV‐OC43, HCoV‐229E, SARS‐CoV‐2, and its major variants by blocking virus entry. Specifically, tetrandrine breaks the interaction between TMPRSS2 and Spike, therefore suppress its priming and the following membrane fusion, and induces Spike to degradation.
Kun Wang, Huiqiang Wang, Shuo Wu, Ge Yang, Haiyan Yan, Lijun Qiao, Xingqiong Li, Mengyuan Wu, Jiandong Jiang, Yuhuan Li   +9 more
wiley   +1 more source

SARS-CoV-2 variants induce distinct disease and impact in the bone marrow and thymus of mice [PDF]

, 2023
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has evolved to variants associated with milder disease. We employed the k18-hACE2 mouse model to study how differences in the course of infection by SARS-CoV-2 variants alpha, delta, and ...
Alves, Nuno L, Costa, Jose Maria, Couto, Joana, Fernandes, Ana Isabel, Ferreirinha, Pedro, Goncalves, Rute, Lamas, Sofia, Madureira, Pedro, Saraiva, Margarida, Silva, Marta L, Silverio, Diogo   +10 more
core  

Treatment of Coronavirus Disease 2019: Shooting in the Dark [PDF]

, 2020
The identification of effective interventions against the coronavirus disease 2019 (COVID-19) pandemic has become a health priority. The rational treatment of a disease is based on the knowledge of its pathophysiology, the identification of a therapeutic
Juan Tamargo
core   +1 more source

The brief overview, antivirus and anti-SARS-CoV-2 activity, quantitative methods, and pharmacokinetics of cepharanthine: a potential small-molecule drug against COVID-19 [PDF]

, 2023
To effectively respond to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an increasing number of researchers are focusing on the antiviral activity of cepharanthine (CEP), which is a clinically approved drug being used for over 70 years ...
Binbin Xia, Hua Cheng, Jiaxin Li, Jing Chen, Jingyao Pang, Li Zheng, Liushui Li, Wenfang Sun, Yali Li, Yang Liu   +9 more
core   +1 more source

Allograft function predicts mortality in kidney transplant recipients with severe COVID-19: a paradoxical risk factor [PDF]

IntroductionKidney transplant recipients (KTRs) are at a higher risk of severe coronavirus disease (COVID-19) because of their immunocompromised status. However, the effect of allograft function on the prognosis of severe COVID-19 in KTRs is unclear.
Han Luo, Han Luo, Hongji Yang, Hongji Yang, Hongji Yang, Jingyu Wen, Qing Ran, Qing Ran, Yifu Hou, Yifu Hou   +9 more
core   +1 more source

Clinical Characteristics and Treatment Efficacy in Patients With SARS‐CoV‐2 Positivity After Nirmatrelvir‐Ritonavir Therapy

Journal of Medical Virology, Volume 97, Issue 5, May 2025.
ABSTRACT Nirmatrelvir‐ritonavir (NMV‐r) has been widely used to treat coronavirus disease 2019 (COVID‐19) for a standard period of 5‐days. However, there are increasing reports of patients with persistent severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) positivity after the standard 5‐day course of NMV‐r treatment.
Huqin Yang, Leyi Gao, Yi Xue, Zhijin Zhang, Lujia Guan, Haifan Zhang, Haomiao Ma, Xuyan Li, Jieqiong Li, Zhaohui Tong   +9 more
wiley   +1 more source

LONG-TERM IMMUNOLOGICAL CONSEQUENCES OF COVID-19 ON HEALTH [PDF]

, 2022
SARS-Cov-2 (severe acute respiratory syndrome coronavirus) that initially came to notice in December 2019 is the agent responsible for COVID-19 is still spreading rapidly worldwide and it is presently a potent danger to the world and also to the economy.
AHER, PRAJWAL, AVHAD, RUPALI, BAJAIT, MANOJ, GADE, NIKHIL, JADHAV, ANIL, KADAM, HARSHADA, KAPHARE, GAURI, TALELE, SWATI   +7 more
core   +1 more source

Clinical characteristics and prognosis of SARS-CoV-2 infection in lung transplant recipients [PDF]

ObjectiveThis study aimed to investigate the clinical manifestations and prognosis of lung transplant (LTx) recipients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during the coronavirus disease (COVID-19) pandemic ...
Li Wei, Qiangming Li, Shuai Hu, Tian Xia, Wenping Zhang, Zeheng Ma, Zhijun Han, Zibo Zhu   +7 more
core   +1 more source

Effectiveness and safety of azvudine in COVID-19: A systematic review and meta-analysis

PLOS ONE
Objective The aim of this study was to assess the effectiveness and safety of azvudine in treating coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-COV-2). Methods A search was carried out in PubMed, Cochrane Library, Web of Science, medRxiv, and Google Scholar until October 20, 2023.
Bahman Amani, Behnam Amani
openaire   +2 more sources